Rheumnow Podcast cover image

EULAR 2023 Lupus Highlights

Rheumnow Podcast

00:00

UPA to Sit in the B2K Inhibitor

The primary endpoint of week 24, which to me is little early in OP01 studies for the reasons that the pathogenic antibody can last months. They looked at SRI4 plus Prennisone, 10 milligrams or less. There was no added benefit to adding the B2K inhibitor to the UB2-SITNIB.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app